Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400672 | 0.90 | IDO1 (0.46) | RXRARXRBRXRGTACR1SLC6A4 | |
| SCHEMBL27490323 | 0.86 | RXRA (0.45) | RXRARXRBRXRGTACR1SLC6A4 | |
| SCHEMBL17310946 | 0.85 | RXRA (0.51) | RXRARXRBRXRGTACR1SLC6A4 | |
| SCHEMBL4660533 | 0.84 | RXRA (0.41) | RXRARXRBRXRGTACR1SLC6A4 | |
| SCHEMBL19438593 | 0.84 | CAPN1 (0.46) | SLC6A4EPHX1CAPN1ALDH1A1IDO1 | |
| SCHEMBL16503765 | 0.83 | EPHX1 (0.39) | TACR1GPBAR1SLC6A4FFAR4EPHX1 | |
| SCHEMBL28560207 | 0.83 | EPHX1 (0.39) | TACR1GPBAR1SLC6A4FFAR4EPHX1 | |
| SCHEMBL5389064 | 0.83 | RXRA (0.49) | RXRARXRBRXRGTACR1FFAR4 | |
| Hydrochloric Acid SCHEMBL5394073 | 0.81 | RXRA (0.48) | RXRARXRBRXRGTACR1FFAR4 | |
| SCHEMBL3932054 | 0.80 | CYP3A4 (0.44) | RXRARXRBRXRGTACR1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011157670-A2 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157670-A2 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313196-A1 | NOVEL PROCESS | CYP3A5, CYP3A4, GBA1 | RXRA 3424/4885RXRB 3356/4885RXRG 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.